Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer.

Format:

Book

Author/Creator:

Chakraborti, D. S. c.

Language:

English

Physical Description:

1 online resource (1862 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Therapeutics of Natural and Synthetic Compounds in Protease Induced Cancer presents a detailed discussion on the role of therapeutic and synthetic compounds in proteases and how they have been utilized to develop anticancer drugs, covering both their structure and functions.

Contents:

9780443266362v1

Front Cover

Therapeutics of Natural and Synthetic Compounds in Proteaseinduced Cancer

Copyright Page

Dedication

Contents

List of contributors

Preface to Volume 1

I. Volume I: Therapeutic aspects of some natural compounds in proteases-induced cancer

A. General aspects

1 Role of matrix metalloproteinases in triple negative breast cancer

1.1 Introduction

1.2 Matrix metalloproteinases

1.2.1 Matrix metalloproteinases structure

1.2.2 Matrix metalloproteinases classification

1.3 Role of matrix metalloproteinases in triple-negative breast cancer

1.4 Prognostic and predictive markers

1.5 Conclusion and future perspectives

References

2 Effects of natural products on proteases associated with cancers

2.1 Introduction

2.1.1 Natural compounds

2.1.2 Advantages of natural compounds in proteases to prevent diseases

2.1.3 Cancer and signaling pathways

2.1.4 Natural compounds with their associated anticancer activities

2.2 Role of proteases in cancer

2.3 Targeting proteases to prevent cancer

2.4 Role of protease inhibitor in cancer progression

2.5 Conclusion

Acknowledgment

Funding

Credit authorship contribution statement

Declaration of competing Interest

3 The impact of polyphenols on protease regulation in cancer therapy

3.1 Introduction

3.2 Overview of polyphenol structures and classes and their therapeutic implications in cancer treatment

3.3 Mechanisms of polyphenol modulation of proteases

3.4 Conclusion and future directions

Acknowledgments

4 Understanding the role of plant-derived protease-inhibitors in cancer therapy: a therapeutic approach

Abbreviations

4.1 Introduction

4.1.1 Proteases in tumorigenesis

4.2 Protease inhibitors in tumorigenesis

4.2.1 Plant derived protease inhibitors.

4.2.1.1 Kunitz trypsin inhibitor

4.2.1.2 Bowman-Birk inhibitors

4.3 Conclusion and future perspectives

Authors' contributions

5 Unveiling phytonutraceuticals as potential photosensitizers in advanced photodynamic cancer therapy

5.1 Introduction

5.2 Photosensitizing properties of phytocompounds

5.3 Types of phytocompounds relevant to photodynamic therapy

5.3.1 Alkaloids

5.3.2 Anthraquinones

5.3.3 Curcumin

5.3.4 Furanocoumarins

5.3.5 Pheophorbide A

5.3.6 Polyacetylenes and thiophenes

5.4 Methods of extraction

5.5 Methods of purification

5.6 Methods of characterization

5.7 Conclusion

B. Inflammation and immune response

6 Caspase response of inflammasomes in breast cancer

6.1 Introduction

6.1.1 Caspase classifications

6.1.2 Initiator Caspases

6.1.3 Executioner Caspases

6.1.4 Inflammatory Caspases

6.2 Inflammasome

6.2.1 Discovery of nucleotide-binding oligomerization domain-like receptor

6.2.2 Structure of nucleotide-binding oligomerization domain-like receptor

6.2.3 Inflammasome: activation and function

6.2.4 Mechanism of NLRP3 signaling

6.3 Evolution of Caspase responses in inflammasome formation

6.3.1 Origins of Caspase signaling

6.3.1.1 Invertebrates

6.3.1.2 Mammals

6.4 Inflammasome and Caspase response in cancer development

6.4.1 The pro-tumorigenic role of inflammasome

6.4.1.1 Breast cancer

6.4.1.2 Gastric cancer

6.4.1.3 Hepatocellular carcinoma

6.4.1.4 Melanoma

6.4.1.5 Colorectal cancer

6.4.2 The tumor-suppressing role of inflammasome

6.4.2.1 Breast cancer

6.4.2.2 Colorectal cancer

6.5 Role of inflammasome-Caspase response in the pathophysiology of BC

6.6 Inflammasomes and downstream breast cancer signaling

6.6.1 IL-1RI/β-catenin pathway.

6.6.2 IL-1β-NF-kB /CREB-Wnt signaling

6.6.3 Wnt/β-catenin pathway

6.7 Role of inflammasome and Caspase-mediated immune cell response

6.7.1 Dendritic cells

6.7.2 T cells

6.7.3 B cells

6.8 Inflammasome and the fate of breast cancer

6.9 Inflammasome as biomarker and future in molecular diagnosis

6.10 The future direction of inflammasome and Caspase response in cancer research

7 Unraveling the role of cysteine cathepsins in tumor microenvironment aiding progression and metastasis of tumor

7.1 Introduction

7.2 Types of cysteine cathepsin

7.2.1 Cathepsin B

7.2.2 Cathepsin C

7.2.3 Cathepsin F

7.2.4 Cathepsin H

7.2.5 Cathepsin K

7.2.6 Cathepsin L

7.2.7 Cathepsin O

7.2.8 Cathepsin S

7.2.9 Cathepsin V

7.2.10 Cathepsin W

7.2.11 Cathepsin X

7.3 Role of cysteine cathepsins in cancer and cancer inflammation

7.3.1 Relation between cysteine cathepsins and angiogenesis and invasion

7.3.1.1 Angiogenesis and invasions

7.3.2 Relation between cysteine cathepsins and metastasis

7.4 Relation between cysteine cathepsins and innate immune cells in progression and metastasis of cancer

7.4.1 Neutrophils

7.4.2 Macrophages

7.4.3 Myeloid derived suppressor cells

7.5 Treatment strategies targeting cathepsins

7.5.1 Targeting cathepsin B

7.5.2 Cathepsin L inhibitors

7.5.3 Cathepsin X and S inhibitors

7.6 Conclusion

Conflict of interest

Authors contribution

8 Metalloproteases: the effectors of inflammation in breast cancer progression

8.1 Introduction

8.2 Matrix metalloproteinases domain structure

8.3 Classification of matrix metalloproteinases

8.4 Tissue inhibitors of metalloproteinases and a disentigrin and metalloproteinases in breast cancer progression.

8.5 Matrix metalloproteinases are upregulated in breast cancer and their pathological implications

8.5.1 Matrix metalloproteinases that are associated with a negative prognosis in breast cancer

8.5.2 Tumoral or stromal matrix metalloproteinase expression and their prognostic significance

8.5.3 Matrix metalloproteinase levels in serum as prognostic biomarkers

8.6 Matrix metalloproteinase induced tumorigenesis in breast cancer

8.6.1 Regulation of cell survival and apoptosis by Matrix metalloproteinases

8.6.2 Matrix metalloproteinases promoting the formation of tumor-specific microenvironment within the stroma leading to tumor growth and metastatic invasion

8.6.3 Matrix metalloproteinases promoting metastatic invasion

8.6.4 Nonenzymatic role of matrix metalloproteinases

8.7 Inflammation, matrix metalloproteinases and breast cancer

8.7.1 The metalloproteinase axis and inflammation in breast cancer

8.7.2 The role of lymphocytic infiltration in breast cancer and its connection with matrix metalloproteinase-axis and tumor-associated inflammation

8.8 Strategies for targeting matrix metalloproteinases in therapeutics

8.8.1 Limited efficacy of broad-spectrum matrix metalloproteinases in clinical trials

8.8.2 Enhancing specificity in small molecule inhibitors

8.8.3 Antibodies targeting matrix metalloproteinases

8.9 Conclusion and future perspectives

Further reading

9 Proteases in immune response, oncogenesis and beyond

9.1 Introduction

9.2 Role of protease in the innate immune response

9.2.1 Proteases in immune cell migration and trafficking

9.2.2 Proteases as mediators of inflammation and in cytokine activation mechanism

9.2.3 Cytokine production and immune response

9.3 Proteases in cell-mediated immune response

9.4 Proteases in the elimination of altered self-cells.

9.5 Proteases in regulating immune responses

9.6 Dysregulation of immune response and cancers

9.7 Therapeutic potential of protease inhibitors in immune-related disorders

9.7.1 Protease Inhibitors as a targeted therapeutic approach for multiple myeloma and B-cell lymphomas

9.8 Conclusion and future perspectives

10 Matrix metalloproteases induced inflammation in head and neck squamous cell carcinoma

10.1 Introduction

10.2 Proteases in neck squamous cell carcinoma

10.3 Matrix metalloproteinases and its role in inflammation

10.3.1 Matrix mtalloproteinase 1

10.3.2 Matrix metalloproteinase 2

10.3.3 Matrix mtalloproteinase 3

10.3.4 Matrix mtalloproteinase 7

10.3.5 Matrix metalloproteinase 9

10.3.6 Other matrix mtalloproteinases

10.4 Signaling pathways associated with proteases causing inflammation

10.5 Conclusion

11 Serine proteases in prostate cancer: unraveling the interplay of inflammation and immune response

11.1 Introduction

11.2 Serine proteases: key players in prostate cancer progression

11.2.1 Kallikrein-related peptidases

11.2.2 Kallikrein-related peptidases in prostate cancer

11.3 Inflammation in prostate cancer: a double-edged sword

11.4 The role of serine proteases in inflammation-induced prostate cancer

11.5 Immune response in prostate cancer: implications for disease progression

11.5.1 Role of innate and adaptive immunity

11.5.2 The enigmatic dance of immune cells: allies or adversaries?

11.5.3 Innate immunity and prostate cancer

11.5.4 Adaptive immunity and prostate cancer

11.6 Serine proteases and immune system: crosstalk and interactions

11.7 Pro-inflammatory signaling pathways and serine protease activation in prostate cancer

11.7.1 Genetic polymorphisms in inflammation-related genes and involved pathways.

11.7.2 Cyclooxygenase 2.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

0-443-26636-0

OCLC:

1535348138